Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights

Area of Science:

• Cardiovascular Medicine
• Metabolic Bone Disease
• Endocrinology

Background:

• Cardiometabolic syndrome (CMS) components, including hypertension, dyslipidemia, and inflammation, are increasingly recognized as risk factors for reduced bone mineral density (BMD).
• These CMS risk factors share common pathogenic pathways with osteoporosis, the most prevalent metabolic bone disease.
• Inflammation, a key factor in atherosclerosis, also significantly contributes to the development of osteoporosis.

Purpose of the Study:

• To review the current evidence linking bone metabolism with cardiometabolic syndrome.
• To highlight significant research on the interaction between bone health and CMS.
• To discuss potential therapeutic strategies for treating both osteoporosis and atherosclerosis.

Main Methods:

• Literature review of existing research on cardiometabolic syndrome and bone metabolism.
• Analysis of studies investigating shared risk factors and pathogenic mechanisms.
• Exploration of potential therapeutic targets and agents.

Main Results:

• Evidence confirms that hypertension, hypertriglyceridemia, and low HDL cholesterol are associated with lower BMD.
• Shared risk factors, particularly inflammation, play a critical role in the pathogenesis of both atherosclerosis and osteoporosis.
• The interplay between CMS and bone health presents a complex clinical challenge.

Conclusions:

• The cardiometabolic syndrome and osteoporosis share common underlying risk factors and pathophysiological pathways.
• Understanding these interactions is crucial for developing integrated treatment approaches.
• Future research should focus on therapies targeting shared pathways for dual benefits in cardiovascular and bone health.